insights_auto
Outlook: 70.0% bullish·0.0% bearish
Go to analysischevron_right
NBIX:NASDAQ
Neurocrine Biosciences, Inc
135,91 $
arrow_upward
+0,58%(+0,78) 1D
135,91 $
0,00% (0,00)
bedtimeAfter hours
Closed: 14 հոկ, 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NBIX...
Open
133,94 $
High
136,57 $
Low
132,25 $
Mkt. cap
13,82 մլրդ
Avg. vol.
1,29 մլն
Volume
0,00
P/E ratio
19,92
52-wk high
186,12 $
52-wk low
122,14 $
EPS
6,82 $
Beta
0,40
Shares outstanding
101,65 մլն
No. of employees
2 հզր
Open
133,94 $
High
136,57 $
Low
132,25 $
Mkt. cap
13,82 մլրդ
Avg. vol.
1,29 մլն
Volume
0,00
P/E ratio
19,92
52-wk high
186,12 $
52-wk low
122,14 $
EPS
6,82 $
Beta
0,40
Shares outstanding
101,65 մլն
No. of employees
2 հզր
News stories
From web sources and news partners
Investing.com UK
·
16 ժամ առաջ
TD Cowen reiterates Neurocrine Bio stock rating on growth outlook By Investing.com
Barron's
·
1 օր առաջ
This Biopharma Stock Offers Compelling Upside After a Pullback
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences, Inc
CEOKevin C. Gorman
Employees2,5 հզր
Founded1992
HeadquartersՍան Դիեգո, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Websiteneurocrine.com